Participated · Series A · Apr 2026

Coultreon Biopharma focuses on developing therapies that target clinically validated pathways in immunology and metabolic diseases, leveraging expertise in disease biology, drug discovery and translational science. Its pipeline centers on selectively modulating salt-inducible kinase (SIK) biology to address key inflammatory pathways. The company's lead program, COL-5671 (formerly O3R-5671), is a highly selective, oral once-daily SIK3 inhibitor currently in Phase 1 clinical studies. Coultreon intends to use the $125M Series A proceeds to support further clinical development of COL-5671. The company is led by CEO Pierre Raboisson and is based in Leuven, Belgium. No revenue, user, founding year or prior-round financial metrics were reported in the article.

Led · Series B · Dec 2025

Aeovian Pharmaceuticals is focused on restoring cellular metabolic quality control through highly selective inhibition of mTORC1 or CD38. Its lead candidate, AV078, is a first-in-class, CNS-penetrant selective mTORC1 inhibitor engineered to bypass the toxicities seen with non-selective mTOR blockers such as everolimus. Following encouraging Phase 1 data, AV078 is being advanced into a Phase 2 proof-of-concept trial for patients with TSC-related refractory epilepsy, a condition that affects roughly one million people worldwide and remains resistant to therapy in about two-thirds of cases. The company’s wholly owned pipeline aims to expand selective mTORC1 inhibition to additional rare and age-related indications. Proceeds from its recent financing will support the Phase 2 study and further pipeline development. Aeovian operates out of Berkeley, California and remains privately held; no revenue or user metrics were disclosed in the article.

Led · Series A · Oct 2025

Curve Biosciences positions itself as the “Whole-Body Intelligence” company focused on lowering the cost and improving the effectiveness of chronic disease management. Its core product suite pairs the Whole-Body Atlas—a manually curated repository said to be the world’s largest collection of tissue samples labeled by organ and disease state—with AI models to create Whole-Body Blood Tests that can anticipate disease onset and guide therapy choices. The resulting platform aims to give actionable insights to patients, insurers, pharmaceutical companies, and physicians. The company’s executive team includes veterans from Genentech, GRAIL, Natera, Counsyl, and Stanford University, bringing deep expertise in precision diagnostics, product development, and AI. Curve intends to use its newly raised capital to complete clinical validation studies and commercialize its tests. Financially, the company has secured $40 million in Series A funding and has not disclosed any revenue or user figures to date. With this capital, Curve Biosciences plans to scale both its data assets and blood-testing operations to support broader market adoption.

Led · Series B · Mar 2025

Character Biosciences integrates genomics, longitudinal clinical datasets, and AI-driven modeling to pinpoint disease drivers and create precision therapeutics for progressive polygenic disorders, beginning with ophthalmology. Its pipeline is led by CTX114, a complement inhibitor for geographic atrophy, and CTX203, a lipid modulator intended to halt progression to advanced AMD. The company is also advancing programs for primary open-angle glaucoma, seeking to address large unmet medical needs in vision care. Recent leadership hires—including a new CMO, Chief Data & Analytics Officer, Head of Clinical Network and Longitudinal Research, and Head of People—strengthen its clinical and data capabilities. Character Bio positions its unique patient data platform as a competitive advantage to improve drug-development success rates. Financially, the firm has secured more than $110 million in Series B funding, providing capital to move its first therapeutic programs toward the clinic.

Participated · Series C · Sep 2024

Arsenal Biosciences develops programmable, autologous T cell therapies using precise CRISPR-mediated insertion of large synthetic DNA cassettes and logic gating to improve tumor targeting. Its full-stack R&D engine and nonviral clinical manufacturing approach aim to generate multifunctional T cell medicines and build a large DNA library of therapeutic integrated circuits. The company is advancing a pipeline that includes programs for ovarian, kidney, and prostate cancers and a collaboration with Bristol-Myers Squibb to co-develop additional solid-tumor candidates. ArsenalBio recently entered the clinic with AB-2100, a second T cell product candidate now in a Phase 1/2 trial for clear-cell renal cell carcinoma, which has received FDA Fast Track designation. The company plans to use new funding to advance lead programs through clinical development, scale manufacturing, and invest in tools and processes for identifying and developing new candidates. ArsenalBio is headquartered in South San Francisco, California. Arsenal Biosciences develops next-generation autologous T cell therapies for solid tumors using precise CRISPR insertion of large synthetic DNA sequences. Its platform generates multifunctional T cell medicines and the company is building an extensive DNA library of therapeutic 'integrated circuits' with logic gating and synthetic features to improve tumor targeting and therapeutic functions. ArsenalBio pairs a computationally driven approach with nonviral clinical manufacturing to pursue enhanced efficacy, safety, and broader access. The company is advancing a pipeline that includes a lead program, AB-1015, for ovarian cancer, with plans to seek FDA IND clearance and first patient dosing later this year. It also has early-stage candidates for kidney, prostate, and other cancer indications. ArsenalBio is headquartered in South San Francisco, California. ArsenalBio is building a programmable cell therapy platform to create more effective and accessible immune cell therapies, initially focused on cancer. The company integrates CRISPR-based genome engineering, scaled high-throughput target identification, synthetic biology, and machine learning to drive discovery and development. ArsenalBio aims to precisely insert significantly larger DNA payloads without viral vectors, encoding broader biological “software” to rewire immune cell circuitry. The approach targets both solid organ and hematologic cancers and seeks to improve efficacy, patient safety, provider costs, and market access. Leadership and scientific founders come from a consortium of academic medical and research institutions and include experienced industry executives in immuno-oncology, cell therapy, and genomics. ArsenalBio was founded in 2019 and is based in South San Francisco.